Pre-Meeting Categorical Seminars
Additional registration fees may apply. Categorical seminar is included for Weekend Only Attendees. *Members who are also members of a Council or Center will receive a $20 discount when registering online for a Physician/Scientist Categorical.
SNMMI's Annual Meeting offers full-day categorical seminars to provide you with a deeper level of understanding as you examine a single topic of clinical, scientific, or academic interest.
AI in the Era of Personalized Nuclear Medicine
Sponsored by Physics, Instrumentation and Data Sciences Council, CMIIT and Pediatric Imaging Council
The confluence of Artificial Intelligence and Big Data has emerged as one of the most exciting and impactful technological developments of the last couple of years. Yet, the adoption of this technology in nuclear medicine and molecular imaging has been significantly slower than in other areas of medical imaging (e.g., CT, MR) and healthcare in general.
In this categorical, you’ll learn the basics of Deep Learning and how you can implement AI technologies in your practice, including assessing medical data security and ethical challenges, Learn how AI can yield significant dose reduction in pediatric imaging and higher sensitivity in Personalized Medicine. Finally, we also cover the promise and limitations of AI in lesion detection, segmentation, characterization.
A New Decade of Molecular Hybrid Imaging in Orthopedics and Rheumatology: Focus on bone and infection/inflammation
Sponsored by General Clinical Nuclear Medicine Council and British Institute of Radiology
This categorical features four (4) thematically linked mini-sessions, providing you with an update on technical advances as well as key clinical applications of PET/CT and SPECT/CT in orthopedics, infectious disease, and rheumatology. The categorical includes  the recent progress in radiopharmaceutical development for musculoskeletal imaging applications and advances in engineering and physics in SPECT/CT, as well as the clinical use of bone SPECT/CT in orthopedics, with a focus on the role of biomechanics in upper and lower limb joint related conditions. [2} Next, you’ll discuss applications of bone PET/CT in orthopedics and related specialties. The third  topic will focus on bone and prosthesis related infections, emphasizing the clinical indications, imaging algorithms, and impact in patient management. The categorical concludes with  a review of FDG-PET/CT in polymyalgia rheumatica and rheumatoid arthritis, and NaF-PET/CT in rare bone disease (fibrous dysplasia, Paget’s disease, bone viability).
Clinical Issues Effecting Diagnosis and Management of Differentiated Thyroid Cancer
Sponsored by Therapy Center of Excellence AND Committee on Radioiodine Theranostics
I-131 therapy remains the most frequently performed radioisotope therapy in the specialty of Nuclear Medicine. Many new articles have been published that are controversial and affect our practice of I-131 therapies for differentiated thyroid cancer and benign disease. This categorical will feature a timely dialogue on these new publications, including a discussion of the clinical impact and controversies of those changes. If you’re a physician or technologists involved in the management of patients with differentiated thyroid cancer, this session addresses your needs to better understand the Martinique Principles from the ATA, ETA, EANM, and SNMMI, as well as other publications and guidelines and how they may affect your practice’s performance and patient outcomes.
Labeling Strategies for Radiopharmaceutical Synthesis: State-of-the-art and Future Prospects
Sponsored by Radiopharmaceutical Sciences Council
New radiopharmaceuticals continue to be approved by the U.S. Food and
Drug Administration (FDA), including new theranostics for cancer treatment.
This is transforming nuclear medicine from a research technique to a powerful
standard of care. It is therefore imperative that radiopharmaceutical
scientists and nuclear medicine professionals keep up to date with state-of-the-art
practices in labeling strategies and radiopharmaceutical synthesis to meet the
rapidly growing demands for nuclear medicine imaging agents and
radiotherapeutics. In this categorical, you’ll examine the breadth of
radionuclides and radiopharmaceuticals in use today—from fundamental design of
radiopharmaceuticals to strategies for labeling of specific bioactive
molecules, and synthesis of PET radiopharmaceuticals, SPECT
radiopharmaceuticals and radiotherapeutics.
Neurodegeneration: From Current Clinical Applications to New Advancements
Sponsored by Brain Imaging Council
In this categorical, you’ll receive a full review and comprehension of the role of molecular imaging in Neurodegenerative diseases, aimed at improving your skills and competency. The content is focused on general participants interested in improving their knowledge in neurodegeneration, as well as in specialists, with the more recent updates in the field.
Nuclear Cardiology in 2020 and Beyond: Image Guided Decision Making
Sponsored by Cardiovascular Council, Correlative Imaging Council, and Physics, Instrumentation and Data Sciences Council
In this categorical, you’ll focus on five themes:  coronary artery disease evaluation (role of clinical risk assessment and biomarkers, SPECT-CT, PET, CCTA and case review),  cardiac sarcoidosis (patient preparation, multimodality approach and case review),  cardiac infections (valvular endocarditis, other cardiac device infections, correlative imaging on CT and case review),  cardiac amyloidosis (imaging protocols, clinical presentation/pathophysiology/treatment, and case review), and  microvascular chest pain and quantitative blood flow estimation (protocols/image analysis, treatment/physiology, and case review). Multimodality imaging will be emphasized and include SPECT, PET, CT and CMR imaging.
Pearls and Pitfalls of Common Nuclear Medicine Procedures
Sponsored by Advanced Associate Council and General Clinical Nuclear Medicine Council
In this categorical, you’ll explore the best practices and challenges in performing common nuclear medicine procedures and improve the quality of nuclear medicine performed at local institutions. 15 speakers, 30 minutes per speaker, 5 topics, each covered by technologist, Nuclear Medicine Advanced Associates (NMAAs) and physician. The focus will be on quality of nuclear medicine procedures fostered by different level providers working together.
Targeted Molecular Imaging and Radiotheranostics of Prostate Cancer
Sponsored by Therapy Center of Excellence, PET Center of Excellence and Correlative Imaging Council
There has been tremendous growth of molecular imaging and therapy of prostate cancer. Many different PET radiopharmaceuticals are now widely available and provide accurate identification of biochemical recurrent prostate cancer. Several PSMA and other targeted PET agents are also being used clinically and in research settings. In addition to molecular imaging radiopharmaceuticals, many radiotherapeutic options are available for both osseous and soft tissue prostate cancer metastatic disease. In this categorical, you’ll review the currently available agents as well as how molecular imaging and therapy will be affected in the short term. An oncologist perspective will be included in the session and there will be group discussions with the speakers to help you understand the various routes available for optimal patient care.